South Korean biopharmaceutical company Celltrion to invest $330 million to acquire manufacturing facilities owned by Eli Lilly (LLY.US).

According to the Wisdom Financial APP, South Korean biopharmaceutical company Celltrion stated in its submitted regulatory filing on Tuesday that its US subsidiary has acquired a biologic drug manufacturing facility located in Branchburg, New Jersey, USA from Eli Lilly (LLY.US) for $330 million. Celltrion stated in a statement that the company plans to complete the factory acquisition process by the end of this year with the cooperation of its partners.